MedTrace Logo

Cardiovascular Effects of Selective I(f)-Channel Blockade

NCT00865917 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2009-03-19

No results posted yet for this study

Summary

The study compares three treatment modalities in a human model of Postural orthostatic tachycardia syndrome (POTS): beta-blockers, I(f)-blockers, and placebo.

Conditions

  • Postural Orthostatic Tachycardia Syndrome

Interventions

DRUG

beta-blocker (Metoprolol)

Metoprolol 95 mg once per day

DRUG

I(f)-blocker (ivabradine)

ivabradine 7.5 mg once per day

DRUG

Placebo

matching appearance

Sponsors & Collaborators

  • Charite University, Berlin, Germany

    collaborator OTHER

  • Hannover Medical School

    lead OTHER

Principal Investigators

  • Jens Jordan, MD · Hannover Medical School

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2010-11-30
Completion
2010-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00865917 on ClinicalTrials.gov